RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target

September 19, 2016 1:52 PM EDT
Get Alerts SRPT Hot Sheet
Price: $32.99 +2.45%

Rating Summary:
    16 Buy, 9 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 10 | Down: 30 | New: 42
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

RBC Capital upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Sector Perform to Outperform with a price target of $83.00 (from $5.00).

Analyst Simos Simeonidis commented, "In one of the most perplexing regulatory decisions in recent history, FDA has granted accelerated approval to Sarepta's eteplirsen. This decision, which may have a number of negative consequences for the review of rare disease drugs, is a major game-changer for SRPT, which we believe now becomes one of the most attractive M&A targets in biopharma, given both eteplirsen and its pipeline of exon-skipping compounds."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, Rumors, Upgrades

Related Entities

RBC Capital

Add Your Comment